FDA Approves Garetosmab for Rare Bone Condition
The new drug provides a third treatment option for patients with FOP by reducing abnormal bone formation.
Updated on Oct. 29, 2026 in Arthritis

In August 2026, the FDA approved garetosmab for treating fibrodysplasia ossificans progressiva (FOP). This condition causes muscle, tendons, and connective tissue to turn into bone, and this new drug represents one of three treatment options now available to patients.
Why it matters
The approval of garetosmab expands the options for managing FOP, a rare condition that results in the progressive conversion of soft tissue into bone. This development follows two decades of research into the genetic mutations that cause the disease.
Garetosmab showed a 90 percent reduction in new abnormal bone formation in patients with fibrodysplasia ossificans progressiva. This monoclonal antibody is one of three approved treatments for the condition, alongside zilurgisertib and palovarotene.
The players
Regeneron
A biotechnology company that manufactures garetosmab and researches treatments for rare genetic diseases.
Food and Drug Administration
The federal agency responsible for evaluating the safety and efficacy of medical treatments in the United States.
Jordyn Bugarin
A 22-year-old patient who lives with fibrodysplasia ossificans progressiva.
The details
Garetosmab acts as a monoclonal antibody that targets the biological pathways triggering abnormal ossification in individuals with FOP. It joins zilurgisertib, which works by inhibiting the ALK2 protein, to prevent the soft tissues from hardening. These interventions are critical because they address the systemic transformation of soft tissues into bone that defines the disease.
Timeline
2006: The mutated gene causing FOP was discovered.
August 2026: The FDA approved garetosmab for FOP treatment.
Health Landscape
The approval of garetosmab follows the 20-year research arc since the discovery of the FOP gene. It signals a shift in the treatment landscape, which now includes three distinct therapeutic options for this rare condition.
Patients and families affected by FOP should consult with a specialist to understand how new treatment options like garetosmab fit into existing care plans. Because this is a rare and complex disease, ongoing discussions with a physician are essential for evaluating the latest approved therapies.
The takeaway
The treatment landscape for FOP has evolved significantly with the availability of three distinct therapies. Patients and their families should continue to monitor updates from their care teams regarding how new treatments may change clinical management protocols.
Further reading
Learn more about the latest developments in joint and bone health in our Arthritis section.
Source note: This article includes information reported by The New York Times.





